Pharma Mar, S.A. (0RC6) Q3 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning to everyone. I would like to welcome to our third quarter results conference call. On the call with me today are Maria Luisa de Francia, Chief Financial Officer, Luis Mora, Managing Director of Pharmamar, and Pascal Vesman, which is the Vice President of Strategic Development. Following our prepared remarks today, we'll open the line for questions, as we always do. And I would like to remind you that today's conference call might include forward-looking statements regarding future events or the future financial and operating performance of the company. Such forward-looking statements are only predictions based on our current expectations, and actual results might vary from those projected. We disclaim any obligations to update any information provided herein. And we refer you to a safe harbor statement on our corporate presentation, which is available on our website together with the press release and the report of the results we released yesterday. Well, as shown in the preceding quarters of this year, in the third quarter, our commitment to increase our investment in R&D remains evident. Most of these R&D investment is in oncology, and we're making substantial progress in advancing our development efforts. It is worth highlighting that LAWN trial, which represents the confirmatory phase three study of lorinectadine as monotherapy in second line for small cell lung cancer, is recruiting, or recruiting is proceeding as planned. We're also making significant headway in the preparatory work for launching the phase two, three trial of lorbinactidine in first-line leiomyosarcoma, which we expect to start shortly. Also, in oncology, we're actively engaged in early-stage clinical trials with other molecules like ectobactidine, PM534, and PM54. These underscore...